ODYSSEY trial
Study / Research
A cardiovascular outcome trial for Alirocumab (a PCSK9 inhibitor) in patients with recent acute coronary syndrome, showing a 15% reduction in major adverse cardiovascular events.
Mentioned in 2 videos
Save the 2 videos on ODYSSEY trial to your own pod.
Sign up free to keep building your knowledge base on ODYSSEY trial as more episodes are added.
Videos Mentioning ODYSSEY trial
Cardiovascular disease & why we should change the way we assess risk | The Peter Attia Drive Podcast
Peter Attia MD
A clinical trial similar to the FOURIER trial, which likely showed a greater risk reduction due to patients starting at higher LDL-C levels.
230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more
Peter Attia MD
A cardiovascular outcome trial for Alirocumab (a PCSK9 inhibitor) in patients with recent acute coronary syndrome, showing a 15% reduction in major adverse cardiovascular events.